Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Baillie Gifford -International Concentrated Growth. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD+4.07%
YTD+0.67%
Annualized+10.71%
Positioning StanceBULLISH
Market CapAll Cap
GeographyEmerging markets, Europe, Global
Digest Analysis
Quick Take
"Enterprise adoption of artificial intelligence and mRNA oncology breakthroughs are accelerating commercial productivity, reinforcing high-conviction global equity allocations across advanced semiconductor foundries, platform data aggregators."
Executive Summary
The Baillie Gifford International Concentrated Growth ETF generated a net NAV return of +4.07% (+2.48% market price) in the third quarter of 2026, bringing year-to-date net NAV performance to +0.67% and outperforming its benchmark, the MSCI ACWI ex US Index, which advanced +0.57% during the quarter. Over longer horizons, the concentrated strategy has delivered an annualized net return of +10.71% since its December 2017 predecessor inception. Active share stood at 88% across 28 portfolio holdings, with cash representing a negligible 0.05%. Emerging Markets represented the largest regional allocation at 46.70%, followed by Europe ex-UK at 34.15% and North America at 14.62%, with top sector weightings heavily focused on Information Technology (33.91%) and Consumer Discretionary (28.04%).
The managerial framework views global markets through the lens of early-stage structural revolutions, predominantly the rapid expansion of artificial intelligence, advanced semiconductors, and biotechnology breakthroughs. The team stresses that while significant technology installation cycles often experience interim capital misallocation, real enterprise returns from AI deployment are increasingly evident. Hardware infrastructure demand remains structural, as lower costs per compute unit stimulate broader software adoption and push computational demands into physical automation, such as autonomous transport and robotics.
Portfolio activity was marked by disciplined capital recycling and risk-adjusted position sizing. The managers trimmed their position in Moderna following a sharp share-price recovery sparked by positive phase 3 personalized cancer vaccine trial data. Complete exits were executed in Delivery Hero and Exail Technologies following acquisition offers from Uber and Thales, respectively, which curtailed further upside. Reallocated capital funded additions to recent positions in contract drug manufacturer Lonza and battery technology leader Contemporary Amperex Technology (CATL), reinforcing core portfolio exposures to complex therapeutics and global electrification.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
82%
CautiousHigh
High Conviction (82%)
Portfolio construction exhibits high concentration with only 28 active holdings, an 88% active share, and a 14.38% top weighting in TSMC. Position sizing decisions are decisive, demonstrated by fully exiting holdings whose upside was capped by takeover bids and opportunistically trimming Moderna following a strong rebound.
Growth Outlook
72%
BearishBullish
Bullish (72%)
Management maintains a constructive outlook on transformational growth businesses, highlighting accelerating productivity gains from artificial intelligence and major medical breakthroughs. The narrative emphasizes long-term fundamental expansion over near-term macro noise.
Risk Appetite
85%
DefensiveAggressive
Aggressive (85%)
Capital remains almost fully deployed with cash at just 0.05% and significant exposure to volatile growth sectors, notably 33.91% in Information Technology and 28.04% in Consumer Discretionary. Emerging Markets represent 46.70% of assets, reflecting a strong willingness to absorb equity volatility.
Capital Deployment
55%
De-riskingDeploying
Net Neutral (55%)
Portfolio cash holdings remained steady at a minimal 0.05%, reflecting an already fully invested stance. Tactical portfolio adjustments were self-funded, using cash generated from trims in Moderna and complete M&A liquidations to expand stakes in Lonza and CATL.
Forward Guidance
70%
CautiousExpansionary
Expansionary (70%)
The team plans to maintain material exposure across semiconductor equipment and foundries while scaling recent high-conviction additions like Lonza and CATL. Reinvestment of proceeds from M&A exits confirms an ongoing deployment bias into structural compounders.
Language Signal
75%
BearishBullish
Bullish (75%)
The letter's language is predominantly optimistic, centered around breakthrough innovations, durable competitive advantages, and the early stages of an industrial revolution. Mentions of risks are tied to temporary capital misallocations rather than macro vulnerability.
Perceived Risk
35%
Low RiskElevated
Moderate Risk (35%)
Macroeconomic headwinds receive little direct attention, with risk discussion predominantly focused on standard technology adoption cycles and interim capital misallocation. Broad systemic or credit hazards are not viewed as structural threats.
Opportunity Density
70%
ScarceAbundant
Abundant (70%)
The managers continue uncovering compelling investment opportunities across physical AI applications, advanced memory technology, and complex biopharmaceuticals. Selectivity remains essential, but the prospective pipeline of transformational businesses is described as rich.
Time Horizon
95%
Short-TermLong-Term
Decade+ (95%)
The fund operates explicitly under a decade-plus investment framework, intentionally underwriting businesses capable of compounding value across complete technological installation cycles. Short-term market quarterly fluctuations are firmly deprioritized.